A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors

PURPOSE: Vorinostat (V) at levels >2.5 μM enhances chemotherapy in vitro. Yet the approved oral dose of 400 mg inconsistently achieves this level in patients. We developed an intermittent oral pulse-dose schedule of V to increase serum levels. We combined V with the cyclin dependent kinase inhibi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Dickson, Mark Andrew, Rathkopf, Dana E., Carvajal, Richard D., Grant, Steven, Roberts, John D., Reid, Joel M., Ames, Matthew M., McGovern, Renee M., Lefkowitz, Robert A., Gonen, Mithat, Cane, Lauren M., Dials, Heather J., Schwartz, Gary K.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2010
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3545439/
https://ncbi.nlm.nih.gov/pubmed/20461440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9447-x
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items